Trial Profile

Evaluation of Neointimal Healing of Endothelial Progenitor Cell Capturing Sirolimus-Eluting (COMBO) Stent by Optical Coherence Tomography: the EGO-COMBO Pilot Study.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CD34 monoclonal antibody/sirolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis
Focus Therapeutic Use
Acronyms EGO-COMBO

Most Recent Events

29 Oct 2013 24 month results presented at TCT 2013, according to an OrbusNeich meda release.
14 Mar 2012 Planned End Date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
14 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com